Which medications in the drug class Pulmonary, Tyrosine Kinase Inhibitors are used in the treatment of Restrictive Lung Disease?

Updated: Sep 16, 2020
  • Author: Jonathan Robert Caronia, DO; Chief Editor: John J Oppenheimer, MD  more...
  • Print

Pulmonary, Tyrosine Kinase Inhibitors

These agents target numerous intracellular pathways to reduce the fibrosis process by interrupting cell signaling pathways.

Nintedanib (Ofev)

Nintedanib is a tyrosine kinase inhibitor that targets growth factors that have been shown to potentially be involved in pulmonary fibrosis (eg, vascular endothelial growth factor receptor [VEGFR], fibroblast growth factor receptor [FGFR], platelet derived growth factor receptor [PDGF]).

Pirfenidone (Esbriet)

Pirfenidone is an inhibitor of transforming growth factor-beta (TGF-β), and it also inhibits the synthesis of tumor necrosis factor-alpha (TNF-α).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!